晶泰控股-P(02228.HK) 公布，完成对或然生物(Alternative Bio)的战略投资，并建立深度研发合作。双方正基于或然生物在全球未满足的临床需求领域所发现的First-in-Class(首创新药)靶点，共同推进创新药物研发。
晶泰科技首席科学官张佩宇认为或然生物在蛋白翻译调控及疾病机制解析领域的前沿突破，为一系列突破性的靶点发现提供全新可能；期待与世界级科学家的紧密协作，充分发挥晶泰科技AI+机器人药物研发平台在跨越传统药研瓶颈、快速实现创新突破方面的成功经验与技术优势，以前沿技术赋能临床转化，为未满足的临床需求开发突破性疗法。
或然生物联合创始人、首席运营官杨彬表示，期待在AI新药研发平台赋能下加快速度，开发出更多高特异性、低毒副作用和具有巨大临床价值的小分子抑制剂，将优质高效的药物尽早带给全球患者。
晶泰现报6.47元，升9.48%，成交1.32亿股，涉资8.53亿元。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-07 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.